 <h1>Morgidox Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>doxycycline</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about doxycycline. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Morgidox.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to doxycycline: oral capsule, oral capsule extended release, oral powder for suspension, oral syrup, oral tablet, oral tablet delayed release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, doxycycline (the active ingredient contained in Morgidox) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking doxycycline:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>feeling of discomfort</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>hives or welts, itching, or rash</li>
<li>increased thirst</li>
<li>indigestion</li>
<li>inflammation of the joints</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>numbness or tingling of the face, hands, or feet</li>
<li>pain in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>red skin lesions, often with a purple center</li>
<li>redness and soreness of the eyes</li>
<li>redness of the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach cramps</li>
<li>stomach pain or tenderness</li>
<li>swelling of the feet or lower legs</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight loss</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of doxycycline may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>bulging soft spot on the head of an infant</li>
<li>change in the ability to see colors, especially blue or yellow</li>
<li>chest pain, discomfort, or burning</li>
<li>cracks in the skin</li>
<li>decrease in vision</li>
<li>difficulty breathing</li>
<li>discoloration of the thyroid glands</li>
<li>double vision</li>
<li>general body swelling</li>
<li>heartburn</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>loss of heat from the body</li>
<li>lower back or side pain</li>
<li>nosebleeds</li>
<li>pain or burning in the throat</li>
<li>pain with swallowing</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>red, swollen skin</li>
<li>redness or other discoloration of the skin</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>scaly skin</li>
<li>severe nausea</li>
<li>severe stomach pain</li>
<li>severe sunburn</li>
<li>tooth discoloration</li>
<li>unusual bleeding or bruising</li>
<li>vomiting blood</li>
</ul><p>
<!-- end oral capsule, oral capsule extended release, oral powder for suspension, oral syrup, oral tablet, oral tablet delayed release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doxycycline: injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral kit, oral powder for reconstitution, oral syrup, oral tablet, oral and topical kit</i></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%)</p>
<p><b>Common</b> (1% to 10%): Sinus headache</p>
<p><b>Rare</b> (0.01% to 0.1%): Bulging fontanels (in infants), benign intracranial hypertension (pseudotumor cerebri [symptoms include blurred vision, scotomata, diplopia]), tinnitus</p>
<p><b>Frequency not reported</b>: Hypoesthesia, increased intracranial pressure, paresthesia, somnolence, stupor, taste loss, drowsiness, amnesia, paresthesias of body areas exposed to sunlight, phrenic nerve paralysis after sclerotherapy</p>
<p><b>Postmarketing reports</b>: Pseudotumor cerebri, headache, dizziness<sup>[Ref]</sup></p><p>Benign intracranial hypertension resulting in permanent loss of vision has been reported.</p>
<p></p>
<p>A 70-year-old female patient with no significant medical history suddenly developed a severe headache followed by vomiting about 15 minutes after the initial dose of this drug.  The patient also experienced memory dysfunction; she could not remember the events of the afternoon prior to the dose of this drug and could not retain the information after she was reminded.  The incident lasted about 30 minutes and she was transported to the hospital for further evaluation.  No further cause, such as intoxication or trauma, could be elicited.  Once at the hospital, the patient was able to remember the events of the afternoon and could retain new information, but amnesia regarding the events of the 30 minutes following the onset of the headache persisted.  The patient's laboratory results, computerized tomography scan, MRI scan, cerebrospinal fluid, and electroencephalogram showed no pathology.  When the patient was discharged 2 days later, the amnesia for the 30 minutes continued.  After elimination of other symptomatic causes, the amnesia was concluded to be due to this drug because of the close relation of the dose and the onset of symptoms.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Common cold (up to 22%), influenza symptoms (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Injury/accidental injury, pain, infection, fungal infection, influenza</p>
<p><b>Rare</b> (0.01% to 0.1%): Candida infection/candidiasis, flushing, retrosternal pain</p>
<p><b>Frequency not reported</b>: Malaise, overgrowth of nonsusceptible organisms (superinfection)</p>
<p><b>Postmarketing reports</b>: Asthenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 13.4%)</p>
<p><b>Common</b> (1% to 10%): Nausea/vomiting, toothache, tooth disorder, dyspepsia, diarrhea, periodontal abscess, acid indigestion, upper abdominal pain, abdominal distention, abdominal pain, stomach discomfort, dry mouth</p>
<p><b>Uncommon</b> (0.1% to 1%): Gum pain, heartburn/gastritis</p>
<p><b>Rare</b> (less than 0.1%): Glossitis, dysphagia, enterocolitis, inflammatory lesions (with candidal/monilial overgrowth) in the anogenital region, esophagitis, esophageal ulcerations, pancreatitis, pseudomembranous colitis, Clostridium difficile colitis, stomatitis</p>
<p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, esophageal irritation, ulceration, epigastric burning, black hairy tongue, tooth discoloration/adult tooth staining, vomiting, enamel hypoplasia, staphylococcal enterocolitis</p>
<p><b>Postmarketing reports</b>: Bloody diarrhea, colitis, constipation, superficial tooth discoloration<sup>[Ref]</sup></p><p>Numerous cases of esophageal ulceration have been reported.  In most cases, the patients had taken their medication at bedtime, usually without enough liquid.  Patients often presented with severe retrosternal pain and difficulty swallowing.  Ulcerations generally resolved within a week after discontinuing the drug.  In 1 case report, severe hiccups of 4-day duration associated with esophagitis followed the first dose of this drug.</p>
<p></p>
<p>Esophagitis and esophageal ulcerations have been reported in patients taking the capsule or tablet formulations of tetracycline-class antibiotics.  Most of these patients took the drug immediately before going to bed.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint pain/arthralgia, back pain/back ache</p>
<p><b>Uncommon</b> (0.1% to 1%): Muscle pain/myalgia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, sore throat, sinus congestion, coughing, sinusitis, bronchitis, nasal congestion, pharyngolaryngeal pain</p>
<p><b>Frequency not reported</b>: Bronchospasm</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (including maculopapular rash, erythematous rash), photosensitivity reaction/dermatitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, photoonycholysis, drug reaction with eosinophilia and systemic symptoms (DRESS)</p>
<p><b>Frequency not reported</b>: Nail discoloration, phototoxicity, photoallergic reaction, morbilliform rash, onycholysis, pustular rash</p>
<p><b>Postmarketing reports</b>: Pruritus, urticaria</p>
<p></p>
<p>Tetracyclines:</p>
<p>-Frequency not reported: Hyperpigmentation<sup>[Ref]</sup></p><p>In a double-blinded study, this drug was found to be more phototoxic than minocycline and demeclocycline.  Paresthesias of the body areas exposed to sunlight may be early signs of sunburn reactions.</p>
<p></p>
<p>A case report of a possible photoallergic reaction described scaly erythema and vesicles on the face and neck associated with administration of this drug.  Upon rechallenge, a flare with erythema, itching, and burning occurred in the same area.</p>
<p></p>
<p>Another case report was documented in Australian troops treated with 100 mg daily for malaria prophylaxis while on deployment in East Timor, a group of islands within the Malaysian archipelago located close to the equator.  Of the 135 troops, 22 exhibited phototoxic reactions to low doses of this drug that resembled severe sunburn with erythematous plaques on the sun-exposed areas.  The troops used a sunscreen containing oxybenzone.</p>
<p></p>
<p>An 11-year-old boy treated with this drug for brucellosis was evaluated for painless brown nail discoloration.  This drug was initiated for brucellosis but stopped when the boy developed photosensitivity, but 15 days after the initiation of therapy brown nail discoloration developed.  Other than the brown discoloration, the boy's physical condition was normal and the discoloration disappeared within 1 month.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstrual cramps, bacterial vaginitis, vulvovaginal mycotic infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Vaginal infection</p>
<p><b>Frequency not reported</b>: Vaginal itch, vaginitis</p>
<p><b>Postmarketing reports</b>: Vaginal candidiasis/moniliasis, anogenital moniliasis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, increased blood pressure</p>
<p><b>Frequency not reported</b>: Phlebitis (with IV administration)</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased AST</p>
<p><b>Rare</b> (0.01% to 0.1%): Abnormal hepatic function, hepatic failure, hepatitis, hepatotoxicity, jaundice</p>
<p><b>Frequency not reported</b>: Acute hepatocellular injury, cholestatic reactions, cholestatic hepatitis, fatty liver degeneration, transient increases in liver function tests<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia in a nondiabetic patient has been reported.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased blood LDH, increased blood glucose</p>
<p><b>Rare</b> (0.01% to 0.1%): Decreased appetite, porphyria</p>
<p><b>Frequency not reported</b>: Hypoglycemia, anorexia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety</p>
<p><b>Frequency not reported</b>: Confusion, depression, hallucination</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactic reaction (including angioedema, exacerbation of systemic lupus erythematosus, pericarditis, hypersensitivity, serum sickness, Henoch-Schonlein purpura, hypotension, dyspnea, tachycardia, peripheral edema, urticaria)</p>
<p><b>Frequency not reported</b>: Hypersensitivity reactions (including urticaria, angioneurotic edema, anaphylactic shock, anaphylaxis, anaphylactoid reactions, anaphylactoid purpura, serum sickness, hypotension, pericarditis, exacerbation of systemic lupus erythematosus, dyspnea, peripheral edema, tachycardia)</p>
<p><b>Postmarketing reports</b>: Mild allergic reactions<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia</p>
<p><b>Frequency not reported</b>: Increased prothrombin time, leukopenia, thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Increased BUN/blood urea (dose-related)</p>
<p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Endocrine</h3><p>The long-term use of tetracyclines has been associated with microscopic brown-black discoloration of the thyroid gland; abnormal thyroid function has not been reported.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Microscopic brown-black discoloration of the thyroid gland<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Diplopia, papilledema, loss of vision (associated with drug-induced benign intracranial hypertension), conjunctivitis, periorbital edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Tetracyclines:</p>
<p>-Frequency not reported: Autoimmune syndromes</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Kirse DJ, Suen JY, Stern SJ "Phrenic nerve paralysis after doxycycline sclerotherapy for chylous fistula." Otolaryngol Head Neck Surg 116 (1997): 680-3</p><p id="ref_2">2. Heveling T,  Kubalek R "Doxycycline-induced amnesia : a case report." Eur J Clin Pharmacol 63 (2006): 95-6</p><p id="ref_3">3. "Product Information. Acticlate (doxycycline)." Aqua Pharmaceuticals LLC, Malvern, PA. </p><p id="ref_4">4. Tabibian JH,  Gutierrez MA "Doxycycline-induced pseudotumor cerebri." South Med J 102 (2009): 310-1</p><p id="ref_5">5. Digre KB "Not so benign intracranial hypertension." BMJ 326 (2003): 613-4</p><p id="ref_6">6. Del Rosso JQ,  Webster GF,  Jackson M, et al. "Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea." J Am Acad Dermatol 56 (2007): 791-802</p><p id="ref_7">7. Hasin T,  Davidovitch N,  Cohen R, et al. "Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med 355 (2006): 148-55</p><p id="ref_8">8. Friedman DI,  Gordon LK,  Egan RA, et al. "Doxycycline and intracranial hypertension." Neurology 62 (2004): 2297-9</p><p id="ref_9">9. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_10">10. "Product Information. Adoxa (doxycycline)." Doak Dermatologics Division, Fairfield, NJ. </p><p id="ref_11">11. "Product Information. Periostat (doxycycline)" Collagenex Pharmaceuticals, Newtown, PA. </p><p id="ref_12">12. "Product Information. Vibramycin (doxycycline)." Pfizer US Pharmaceuticals, New York, NY. </p><p id="ref_13">13. Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980): 27</p><p id="ref_14">14. Akhyani M,  Ehsani AH,  Ghiasi M,  Jafari AK "Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial." Int J Dermatol 47 (2008): 284-8</p><p id="ref_15">15. Story MJ, McCloud PI, Boehm G "Doxycycline tolerance study: incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs vibramycin')." Eur J Clin Pharmacol 40 (1991): 419-21</p><p id="ref_16">16. Tzianetas I, Habal F, Keystone JS "Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria." Am J Trop Med Hyg 54 (1996): 203-4</p><p id="ref_17">17. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12</p><p id="ref_18">18. Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984): 223</p><p id="ref_19">19. Nelson R,  Parker SR "Doxycycline-induced staining of adult teeth: the first reported case." Arch Dermatol 142 (2006): 1081-2</p><p id="ref_20">20. Golledge CL, Riley TV "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet 345 (1995): 1377-8</p><p id="ref_21">21. Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994): 1185-7</p><p id="ref_22">22. Ramsakal A,  Mangat L "Images in clinical medicine. Lingua villosa nigra." N Engl J Med 357 (2007): 2388</p><p id="ref_23">23. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_24">24. Croft AM,  Jackson CJ,  Darbyshire AH "Doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med 355 (2006): 1614; author reply 1614-5</p><p id="ref_25">25. Adverse Drug Reactions Advisory Committee "Doxycycline-induced oesophageal ulceration." Med J Aust 161 (1994): 490</p><p id="ref_26">26. Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985): 1009-11</p><p id="ref_27">27. Hasanjani Roushan MR,  Mohraz M,  Hajiahmadi M,  Ramzani A,  Valayati AA "Efficacy of Gentamicin plus Doxycycline versus Streptomycin plus Doxycycline in the Treatment of Brucellosis in Humans." Clin Infect Dis 42 (2006): 1075-80</p><p id="ref_28">28. "Low-Dose Doxycycline (Oracea) for Rosacea." Med Lett Drugs Ther 49 (2007): 5-6</p><p id="ref_29">29. Grochenig HP,  Tilg H,  Vogetseder W "Clinical challenges and images in GI. Pill esophagitis." Gastroenterology 131 (2006): 996, 1365</p><p id="ref_30">30. de Vries HJ,  Smelov V,  Middelburg JG,  Pleijster J,  Speksnijder AG,  Morre SA "Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment." Clin Infect Dis 48 (2009): e53-6</p><p id="ref_31">31. "Product Information. Oracea (doxycycline)." Collagenex Pharmaceuticals, Newtown, PA. </p><p id="ref_32">32. Smith K,  Leyden JJ "Safety of doxycycline and minocycline: a systematic review." Clin Ther 27 (2005): 1329-42</p><p id="ref_33">33. Passier A,  Smits-van Herwaarden A,  van Puijenbroek E "Photo-onycholysis associated with the use of doxycycline." BMJ 329 (2004): 265</p><p id="ref_34">34. Lim DS,  Murphy GM "High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor." Br J Dermatol 149 (2003): 213-4</p><p id="ref_35">35. Frost P, Weinstein GD, Gomez EC "Phototoxic potential of minocycline and doxycycline." Arch Dermatol 105 (1972): 681-3</p><p id="ref_36">36. Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A "Photosensitivity due to doxycycline hydrochloride with an unusual flare." Contact Dermatitis 37 (1997): 93-4</p><p id="ref_37">37. Curley RK, Verbov JL "Stevens-Johnson syndrome due to tetracyclines: a case report (doxycycline) and review of the literature." Clin Exp Dermatol 12 (1987): 124-5</p><p id="ref_38">38. Habif TP "Images in clinical medicine. Doxycycline-induced phototoxicity." N Engl J Med 355 (2006): 182</p><p id="ref_39">39. Lewis-Jones MS, Evans S, Thompson CM "Erythema multiforme occurring in association with lupus erythematosus during therapy with doxycycline." Clin Exp Dermatol 13 (1988): 245-7</p><p id="ref_40">40. Akcam M,  Artan R,  Akcam FZ,  Yilmaz A "Nail discoloration induced by doxycycline." Pediatr Infect Dis J 24 (2005): 845-846</p><p id="ref_41">41. Bjornsson E, Lindberg J, Olsson R "Liver reactions to oral low-dose tetracyclines." Scand J Gastroenterol 32 (1997): 390-5</p><p id="ref_42">42. Basaria S,  Braga M,  Moore WT "Doxycycline-induced hypoglycemia in a nondiabetic young man." South Med J 95 (2002): 1353-4</p><p id="ref_43">43. Raeder JC "Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment." Drug Intell Clin Pharm 18 (1984): 481-2</p><p id="ref_44">44. Chan AY,  Liu DT,  Friedman DI,  Gordon LK,  Egan RA "Doxycycline and intracranial hypertension." Neurology 64 (2005): 765-6</p><p id="ref_45">45. Lochhead J,  Elston JS "Doxycycline induced intracranial hypertension." BMJ 326 (2003): 641-2</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long after stopping doxycycline can I drink alcohol?</li>
<li>What is doxycycline hyclate used for?</li>
<li>What are the best antibiotics for pneumonia?</li>
<li>What is the best antibiotic to treat a sinus infection?</li>
<li>Can I take doxycycline hyclate for strep throat?</li>
<li>How long does doxycycline stay in your body after you finish your prescribed amount?</li>
<li>Can I take doxycycline if I am allergic to penicillin?</li>
<li>Can taking doxycycline for acne worsen my skin?</li>
<li>Can you smoke cigarettes or marijuana while on doxycycline hyclate 100mg?</li>
<li>Is doxycycline hydrochloride 100mg a sulfa based drug?</li>
<li>Will it be harmful to take doxycycline with iron supplements?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Morgidox (doxycycline)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antimalarials</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Vibramycin, Monodox, Oracea, Adoxa, ... +7 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Amebiasis</li>
<li>Actinomycosis</li>
<li>Anthrax</li>
<li>Acne</li>
<li data-more-config-id="list-data-resources-conditions">... +50 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doxycycline: injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral kit, oral powder for reconstitution, oral syrup, oral tablet, oral and topical kit</i></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%)</p><p><b>Common</b> (1% to 10%): Sinus headache</p><p><b>Rare</b> (0.01% to 0.1%): Bulging fontanels (in infants), benign intracranial hypertension (pseudotumor cerebri [symptoms include blurred vision, scotomata, diplopia]), tinnitus</p><p><b>Frequency not reported</b>: Hypoesthesia, increased intracranial pressure, paresthesia, somnolence, stupor, taste loss, drowsiness, amnesia, paresthesias of body areas exposed to sunlight, phrenic nerve paralysis after sclerotherapy</p><p><b>Postmarketing reports</b>: Pseudotumor cerebri, headache, dizziness<sup>[Ref]</sup></p><p>Benign intracranial hypertension resulting in permanent loss of vision has been reported.</p><p></p><p>A 70-year-old female patient with no significant medical history suddenly developed a severe headache followed by vomiting about 15 minutes after the initial dose of this drug.  The patient also experienced memory dysfunction; she could not remember the events of the afternoon prior to the dose of this drug and could not retain the information after she was reminded.  The incident lasted about 30 minutes and she was transported to the hospital for further evaluation.  No further cause, such as intoxication or trauma, could be elicited.  Once at the hospital, the patient was able to remember the events of the afternoon and could retain new information, but amnesia regarding the events of the 30 minutes following the onset of the headache persisted.  The patient's laboratory results, computerized tomography scan, MRI scan, cerebrospinal fluid, and electroencephalogram showed no pathology.  When the patient was discharged 2 days later, the amnesia for the 30 minutes continued.  After elimination of other symptomatic causes, the amnesia was concluded to be due to this drug because of the close relation of the dose and the onset of symptoms.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Common cold (up to 22%), influenza symptoms (up to 11%)</p><p><b>Common</b> (1% to 10%): Injury/accidental injury, pain, infection, fungal infection, influenza</p><p><b>Rare</b> (0.01% to 0.1%): Candida infection/candidiasis, flushing, retrosternal pain</p><p><b>Frequency not reported</b>: Malaise, overgrowth of nonsusceptible organisms (superinfection)</p><p><b>Postmarketing reports</b>: Asthenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 13.4%)</p><p><b>Common</b> (1% to 10%): Nausea/vomiting, toothache, tooth disorder, dyspepsia, diarrhea, periodontal abscess, acid indigestion, upper abdominal pain, abdominal distention, abdominal pain, stomach discomfort, dry mouth</p><p><b>Uncommon</b> (0.1% to 1%): Gum pain, heartburn/gastritis</p><p><b>Rare</b> (less than 0.1%): Glossitis, dysphagia, enterocolitis, inflammatory lesions (with candidal/monilial overgrowth) in the anogenital region, esophagitis, esophageal ulcerations, pancreatitis, pseudomembranous colitis, Clostridium difficile colitis, stomatitis</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, esophageal irritation, ulceration, epigastric burning, black hairy tongue, tooth discoloration/adult tooth staining, vomiting, enamel hypoplasia, staphylococcal enterocolitis</p><p><b>Postmarketing reports</b>: Bloody diarrhea, colitis, constipation, superficial tooth discoloration<sup>[Ref]</sup></p><p>Numerous cases of esophageal ulceration have been reported.  In most cases, the patients had taken their medication at bedtime, usually without enough liquid.  Patients often presented with severe retrosternal pain and difficulty swallowing.  Ulcerations generally resolved within a week after discontinuing the drug.  In 1 case report, severe hiccups of 4-day duration associated with esophagitis followed the first dose of this drug.</p><p></p><p>Esophagitis and esophageal ulcerations have been reported in patients taking the capsule or tablet formulations of tetracycline-class antibiotics.  Most of these patients took the drug immediately before going to bed.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint pain/arthralgia, back pain/back ache</p><p><b>Uncommon</b> (0.1% to 1%): Muscle pain/myalgia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, sore throat, sinus congestion, coughing, sinusitis, bronchitis, nasal congestion, pharyngolaryngeal pain</p><p><b>Frequency not reported</b>: Bronchospasm</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (including maculopapular rash, erythematous rash), photosensitivity reaction/dermatitis</p><p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, photoonycholysis, drug reaction with eosinophilia and systemic symptoms (DRESS)</p><p><b>Frequency not reported</b>: Nail discoloration, phototoxicity, photoallergic reaction, morbilliform rash, onycholysis, pustular rash</p><p><b>Postmarketing reports</b>: Pruritus, urticaria</p><p></p><p>Tetracyclines:</p><p>-Frequency not reported: Hyperpigmentation<sup>[Ref]</sup></p><p>In a double-blinded study, this drug was found to be more phototoxic than minocycline and demeclocycline.  Paresthesias of the body areas exposed to sunlight may be early signs of sunburn reactions.</p><p></p><p>A case report of a possible photoallergic reaction described scaly erythema and vesicles on the face and neck associated with administration of this drug.  Upon rechallenge, a flare with erythema, itching, and burning occurred in the same area.</p><p></p><p>Another case report was documented in Australian troops treated with 100 mg daily for malaria prophylaxis while on deployment in East Timor, a group of islands within the Malaysian archipelago located close to the equator.  Of the 135 troops, 22 exhibited phototoxic reactions to low doses of this drug that resembled severe sunburn with erythematous plaques on the sun-exposed areas.  The troops used a sunscreen containing oxybenzone.</p><p></p><p>An 11-year-old boy treated with this drug for brucellosis was evaluated for painless brown nail discoloration.  This drug was initiated for brucellosis but stopped when the boy developed photosensitivity, but 15 days after the initiation of therapy brown nail discoloration developed.  Other than the brown discoloration, the boy's physical condition was normal and the discoloration disappeared within 1 month.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstrual cramps, bacterial vaginitis, vulvovaginal mycotic infection</p><p><b>Uncommon</b> (0.1% to 1%): Vaginal infection</p><p><b>Frequency not reported</b>: Vaginal itch, vaginitis</p><p><b>Postmarketing reports</b>: Vaginal candidiasis/moniliasis, anogenital moniliasis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, increased blood pressure</p><p><b>Frequency not reported</b>: Phlebitis (with IV administration)</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased AST</p><p><b>Rare</b> (0.01% to 0.1%): Abnormal hepatic function, hepatic failure, hepatitis, hepatotoxicity, jaundice</p><p><b>Frequency not reported</b>: Acute hepatocellular injury, cholestatic reactions, cholestatic hepatitis, fatty liver degeneration, transient increases in liver function tests<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypoglycemia in a nondiabetic patient has been reported.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased blood LDH, increased blood glucose</p><p><b>Rare</b> (0.01% to 0.1%): Decreased appetite, porphyria</p><p><b>Frequency not reported</b>: Hypoglycemia, anorexia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety</p><p><b>Frequency not reported</b>: Confusion, depression, hallucination</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactic reaction (including angioedema, exacerbation of systemic lupus erythematosus, pericarditis, hypersensitivity, serum sickness, Henoch-Schonlein purpura, hypotension, dyspnea, tachycardia, peripheral edema, urticaria)</p><p><b>Frequency not reported</b>: Hypersensitivity reactions (including urticaria, angioneurotic edema, anaphylactic shock, anaphylaxis, anaphylactoid reactions, anaphylactoid purpura, serum sickness, hypotension, pericarditis, exacerbation of systemic lupus erythematosus, dyspnea, peripheral edema, tachycardia)</p><p><b>Postmarketing reports</b>: Mild allergic reactions<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia</p><p><b>Frequency not reported</b>: Increased prothrombin time, leukopenia, thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Increased BUN/blood urea (dose-related)</p><p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Endocrine</h3><p>The long-term use of tetracyclines has been associated with microscopic brown-black discoloration of the thyroid gland; abnormal thyroid function has not been reported.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Microscopic brown-black discoloration of the thyroid gland<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Diplopia, papilledema, loss of vision (associated with drug-induced benign intracranial hypertension), conjunctivitis, periorbital edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Tetracyclines:</p><p>-Frequency not reported: Autoimmune syndromes</p><p id="ref_1">1. Kirse DJ, Suen JY, Stern SJ "Phrenic nerve paralysis after doxycycline sclerotherapy for chylous fistula." Otolaryngol Head Neck Surg 116 (1997): 680-3</p><p id="ref_2">2. Heveling T,  Kubalek R "Doxycycline-induced amnesia : a case report." Eur J Clin Pharmacol 63 (2006): 95-6</p><p id="ref_3">3. "Product Information. Acticlate (doxycycline)." Aqua Pharmaceuticals LLC, Malvern, PA. </p><p id="ref_4">4. Tabibian JH,  Gutierrez MA "Doxycycline-induced pseudotumor cerebri." South Med J 102 (2009): 310-1</p><p id="ref_5">5. Digre KB "Not so benign intracranial hypertension." BMJ 326 (2003): 613-4</p><p id="ref_6">6. Del Rosso JQ,  Webster GF,  Jackson M, et al. "Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea." J Am Acad Dermatol 56 (2007): 791-802</p><p id="ref_7">7. Hasin T,  Davidovitch N,  Cohen R, et al. "Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med 355 (2006): 148-55</p><p id="ref_8">8. Friedman DI,  Gordon LK,  Egan RA, et al. "Doxycycline and intracranial hypertension." Neurology 62 (2004): 2297-9</p><p id="ref_9">9. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_10">10. "Product Information. Adoxa (doxycycline)." Doak Dermatologics Division, Fairfield, NJ. </p><p id="ref_11">11. "Product Information. Periostat (doxycycline)" Collagenex Pharmaceuticals, Newtown, PA. </p><p id="ref_12">12. "Product Information. Vibramycin (doxycycline)." Pfizer US Pharmaceuticals, New York, NY. </p><p id="ref_13">13. Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980): 27</p><p id="ref_14">14. Akhyani M,  Ehsani AH,  Ghiasi M,  Jafari AK "Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial." Int J Dermatol 47 (2008): 284-8</p><p id="ref_15">15. Story MJ, McCloud PI, Boehm G "Doxycycline tolerance study: incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs vibramycin')." Eur J Clin Pharmacol 40 (1991): 419-21</p><p id="ref_16">16. Tzianetas I, Habal F, Keystone JS "Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria." Am J Trop Med Hyg 54 (1996): 203-4</p><p id="ref_17">17. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12</p><p id="ref_18">18. Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984): 223</p><p id="ref_19">19. Nelson R,  Parker SR "Doxycycline-induced staining of adult teeth: the first reported case." Arch Dermatol 142 (2006): 1081-2</p><p id="ref_20">20. Golledge CL, Riley TV "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet 345 (1995): 1377-8</p><p id="ref_21">21. Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994): 1185-7</p><p id="ref_22">22. Ramsakal A,  Mangat L "Images in clinical medicine. Lingua villosa nigra." N Engl J Med 357 (2007): 2388</p><p id="ref_23">23. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_24">24. Croft AM,  Jackson CJ,  Darbyshire AH "Doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med 355 (2006): 1614; author reply 1614-5</p><p id="ref_25">25. Adverse Drug Reactions Advisory Committee "Doxycycline-induced oesophageal ulceration." Med J Aust 161 (1994): 490</p><p id="ref_26">26. Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985): 1009-11</p><p id="ref_27">27. Hasanjani Roushan MR,  Mohraz M,  Hajiahmadi M,  Ramzani A,  Valayati AA "Efficacy of Gentamicin plus Doxycycline versus Streptomycin plus Doxycycline in the Treatment of Brucellosis in Humans." Clin Infect Dis 42 (2006): 1075-80</p><p id="ref_28">28. "Low-Dose Doxycycline (Oracea) for Rosacea." Med Lett Drugs Ther 49 (2007): 5-6</p><p id="ref_29">29. Grochenig HP,  Tilg H,  Vogetseder W "Clinical challenges and images in GI. Pill esophagitis." Gastroenterology 131 (2006): 996, 1365</p><p id="ref_30">30. de Vries HJ,  Smelov V,  Middelburg JG,  Pleijster J,  Speksnijder AG,  Morre SA "Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment." Clin Infect Dis 48 (2009): e53-6</p><p id="ref_31">31. "Product Information. Oracea (doxycycline)." Collagenex Pharmaceuticals, Newtown, PA. </p><p id="ref_32">32. Smith K,  Leyden JJ "Safety of doxycycline and minocycline: a systematic review." Clin Ther 27 (2005): 1329-42</p><p id="ref_33">33. Passier A,  Smits-van Herwaarden A,  van Puijenbroek E "Photo-onycholysis associated with the use of doxycycline." BMJ 329 (2004): 265</p><p id="ref_34">34. Lim DS,  Murphy GM "High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor." Br J Dermatol 149 (2003): 213-4</p><p id="ref_35">35. Frost P, Weinstein GD, Gomez EC "Phototoxic potential of minocycline and doxycycline." Arch Dermatol 105 (1972): 681-3</p><p id="ref_36">36. Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A "Photosensitivity due to doxycycline hydrochloride with an unusual flare." Contact Dermatitis 37 (1997): 93-4</p><p id="ref_37">37. Curley RK, Verbov JL "Stevens-Johnson syndrome due to tetracyclines: a case report (doxycycline) and review of the literature." Clin Exp Dermatol 12 (1987): 124-5</p><p id="ref_38">38. Habif TP "Images in clinical medicine. Doxycycline-induced phototoxicity." N Engl J Med 355 (2006): 182</p><p id="ref_39">39. Lewis-Jones MS, Evans S, Thompson CM "Erythema multiforme occurring in association with lupus erythematosus during therapy with doxycycline." Clin Exp Dermatol 13 (1988): 245-7</p><p id="ref_40">40. Akcam M,  Artan R,  Akcam FZ,  Yilmaz A "Nail discoloration induced by doxycycline." Pediatr Infect Dis J 24 (2005): 845-846</p><p id="ref_41">41. Bjornsson E, Lindberg J, Olsson R "Liver reactions to oral low-dose tetracyclines." Scand J Gastroenterol 32 (1997): 390-5</p><p id="ref_42">42. Basaria S,  Braga M,  Moore WT "Doxycycline-induced hypoglycemia in a nondiabetic young man." South Med J 95 (2002): 1353-4</p><p id="ref_43">43. Raeder JC "Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment." Drug Intell Clin Pharm 18 (1984): 481-2</p><p id="ref_44">44. Chan AY,  Liu DT,  Friedman DI,  Gordon LK,  Egan RA "Doxycycline and intracranial hypertension." Neurology 64 (2005): 765-6</p><p id="ref_45">45. Lochhead J,  Elston JS "Doxycycline induced intracranial hypertension." BMJ 326 (2003): 641-2</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long after stopping doxycycline can I drink alcohol?</li>
<li>What is doxycycline hyclate used for?</li>
<li>What are the best antibiotics for pneumonia?</li>
<li>What is the best antibiotic to treat a sinus infection?</li>
<li>Can I take doxycycline hyclate for strep throat?</li>
<li>How long does doxycycline stay in your body after you finish your prescribed amount?</li>
<li>Can I take doxycycline if I am allergic to penicillin?</li>
<li>Can taking doxycycline for acne worsen my skin?</li>
<li>Can you smoke cigarettes or marijuana while on doxycycline hyclate 100mg?</li>
<li>Is doxycycline hydrochloride 100mg a sulfa based drug?</li>
<li>Will it be harmful to take doxycycline with iron supplements?</li>
</ul><h2>More about Morgidox (doxycycline)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antimalarials</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Amebiasis</li>
<li>Actinomycosis</li>
<li>Anthrax</li>
<li>Acne</li>
<li data-more-config-id="list-data-resources-conditions">... +50 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>